Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|May 15, 2002
In short...
VISTAKON vistas: The VISTAKON unit of Johnson & Johnson may spend more than $30 million to build a new research and development center in Jacksonville, FL. The center, to be completed in September 2003, will develop new VISTAKON products.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Ophthalmic care uncommon after tamoxifen initiation
2
FDA requires NAION warning across the GLP-1 receptor agonist class
3
Retinal gene therapy in 2026: 13 milestones from January through October
4
Training refractive surgeons and expanding access to eye surgery
5